Aldeyra Therapeutics, Inc.
Compositions and methods of treating retinal disease
Last updated:
Abstract:
Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed
Status:
Grant
Type:
Utility
Filling date:
7 Jan 2019
Issue date:
9 Feb 2021